By a News Reporter-Staff News Editor at Gene Therapy Weekly -- Investigators discuss new findings in Liver Diseases and Conditions. According to news originating from Yongin, South Korea, by NewsRx correspondents, research stated, "In this review, we discuss recent advances in nucleic acid-based therapeutic technologies that target hepatitis C virus (HCV) infection. Because the HCV genome is present exclusively in RNA form during replication, various nucleic acid-based therapeutic approaches targeting the HCV genome, such as ribozymes, aptamers, siRNAs, and antisense oligonucleotides, have been suggested as potential tools against HCV."
Our news journalists obtained a quote from the research from Dankook University, "Nucleic acids are potentially immunogenic and typically require a delivery tool to be utilized as therapeutics. These limitations have hampered the clinical development of nucleic acid-based therapeutics. However, despite these limitations, nucleic acid-based therapeutics has clinical value due to their great specificity, easy and large-scale synthesis with chemical methods, and pharmaceutical flexibility. Moreover, nucleic acid therapeutics are expected to broaden the range of targetable molecules essential for the HCV replication cycle, and therefore they may prove to be more effective than existing therapeutics, such as interferon-a and ribavirin combination therapy."
According to the news editors, the research concluded: "This review focuses on the current status and future prospects of ribozymes, aptamers, siRNAs, and antisense oligonucleotides as therapeutic reagents against HCV."
For more information on this research see: Prospects for nucleic acid-based therapeutics against hepatitis C virus. World Journal of Gastroenterology, 2013;19(47):8949-8962. World Journal of Gastroenterology can be contacted at: Baishideng Publ Grp Co Ltd, Room 1701, 17-F, Henan Building, No. 90, Jaffe Rd, Wanchai, Hong Kong 100025, Peoples R China. (Baishideng Publishing Group - www.wjgnet.com/; World Journal of Gastroenterology - www.wjgnet.com/1007-9327/current.htm)
The news correspondents report that additional information may be obtained from C.H. Lee, Dankook University, Inst Nanosensor & Biotechnol, Dept. of Mol Biol, Yongin 448701, South Korea. Additional authors for this research include J.H. Kim and S.W. Lee (see also Liver Diseases and Conditions).
Keywords for this news article include: HCV, Asia, Antisense Technology, Biotechnology, Viral, Yongin, Genetics, Virology, Hepatology, South Korea, RNA Viruses, Bioengineering, Gastroenterology, Hepatitis C Virus, Infectious Disease, Combination Therapy, Flaviviridae Infections, Digestive System Diseases, Liver Diseases and Conditions
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC